Spotlight
Video

KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior Blinatumomab Following CAR-T Cell Therapy

Loading........
Description: Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior Blinatumomab Following CAR-T Cell Therapy.
Shared By : Annual-Meeting
Posted on : 06/02/19
Added : 2 months ago